Clinical Features and Computed Tomography Radiomics-Based Model for Predicting Pancreatic Ductal Adenocarcinoma and Focal Mass-Forming Pancreatitis.

Objective

To establish a predictive model distinguishing focal mass-forming pancreatitis (FMFP) from pancreatic ductal adenocarcinoma (PDAC) based on computed tomography (CT) radiomics and clinical data.

Methods

A total of 78 FMFP patients (FMFP group) and 120 PDAC patients (PDAC group) who were admitted to Xiangyang No.1 People's Hospital and Xiangyang Central Hospital from February 2012 to May 2021 and were pathologically diagnosed were included in this study, and were input to set up the training set and test set at a ratio of 7:3. The 3Dslicer software was used to extract the radiomic features and radiomic scores (Radscores) of the 2 groups, and the clinical data (age, gender, etc), CT imaging features (lesion location, size, enhancement degree, vascular wrapping, etc) and CT radiomic features of the 2 groups were compared. Logistic regression was used to screen the independent risk factors of the 2 groups, and multiple prediction models (clinical imaging model, radiomics model, and combined model) were established. Then the receiver operating characteristic (ROC) analysis and decision curve analysis (DCA) were conducted to compare the prediction performance and net benefit of the models.

Results

The multivariate logistic regression results indicated that dilation of the main pancreatic duct, vascular wrapping, Radscore1 and Radscore2 were independent influencing factors for distinguishing FMFP from PDAC. In the training set, the combined model showed the best predictive performance (area under the ROC curve [AUC] 0.857, 95% CI [0.787-0.910]), significantly higher than the clinical imaging model (AUC 0.650, 95% CI [0.565-0.729]) and the radiomics model (AUC 0.812, 95% CI [0.759-0.890]). DCA confirmed that the combined model had the highest net benefit. These results were further validated by the test set.

Conclusion

The combined model based on clinical-CT radiomics data can effectively identify FMFP and PDAC, providing a reference for clinical decision-making.